DNLI Q2 2018 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

DNLIDenali Therapeutics Inc.

$3B

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M

Gross Profit

$2M100.0% margin

Operating Income

-$57M-3481.9% margin

Net Income

-$55M-3320.6% margin

EPS (Diluted)

$-0.59

QoQ Revenue Growth

+157.1%

Cash Flow

Operating Cash Flow

-$42M

Free Cash Flow

-$42M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$572M

Total Liabilities

$82M

Stockholders' Equity

$490M

Cash & Equivalents

$33M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$0	—
Gross Profit	$2M	$0	—
Operating Income	-$57M	-$23M	-154.3%
Net Income	-$55M	-$22M	-147.2%